Cost-utility analysis and budget impact of benralizumab as add-on therapy to standard care for severe eosinophilic asthma in Colombia
Author:
Affiliation:
1. Research group in Pharmacology and Toxicology ”INFARTO”. Department of Pharmacology and Toxicology. University of Antioquia, Medellín, Colombia
2. Hospital Infantil Concejo de Medellín, Colombia
Publisher
Informa UK Limited
Subject
Pharmacology (medical),Health Policy,General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/14737167.2021.1945445
Reference24 articles.
1. 1. To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012;12:204.
2. 2. Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010;181(4):315–23.
3. 3. Sánchez J, Morales E, Santamaria L-C, Acevedo A-M, Calle A, Olivares M, et al. IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma. World Allergy Organization Journal. 2021;14(3):100520.
4. 4. Global Iniciative for Asthma Management and Prevention 2020 [Available from: www.ginaasthma.org.
5. 5. FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–41. **Key reference of efectiveness of benralizumab in Asthma
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Analysis of the clinical and economic effectiveness of using benralizumab in comparison with standard therapy in patients with severe bronchial asthma;FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology;2023-12-30
2. Economic evaluation of biological treatments in patients with severe asthma: a systematic review;Expert Review of Pharmacoeconomics & Outcomes Research;2023-06-09
3. Cost-Effectiveness of Mepolizumab Add-On in the Treatment of Severe Eosinophilic Asthma in Chile;Value in Health Regional Issues;2023-05
4. Cost-Utility of Continuous Positive Airway Pressure for Respiratory Distress in Preterm Infants in a Middle-Income Country;Value in Health Regional Issues;2023-05
5. Incremental net monetary benefit of biologic therapies in moderate to severe asthma: a systematic review and meta-analysis of economic evaluation studies;Journal of Asthma;2023-03-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3